Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
3 Strategic Implications Hanmi Pharmaceuticals continues the ongoing global Phase II SBS trial Eli Lilly and Company gains a differentiated late-stage GI asset Potential expansion into multiple future indications Further diversifies Lillys pipeline beyond obesity, oncology and Alzheimers disease The deal also highlights increasing pharmaceutical interest in gut biology beyond the GLP-1 category that has dominated industry investment over the past several years
Eli Lilly plans to submit orforglipron GLP-1 pill data to the FDA by the end of the year for consideration of the pill for weight loss management, and for Type 2 diabetes management in early 2026
There isnt much about MSMs side effects
Ischemic optic neuropathy (ION) is a rare but serious condition that can cause vision loss or even blindness
